{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-086121","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.572549+00:00","generated_at":"2026-06-24T04:13:46.347085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure Q2 net loss $17.9M; cash $185.5M funds ops into Q1 2024","bullets":["Net loss $17.9M in Q2 2022 vs $18.0M in Q2 2021; no revenue reported.","Cash, equivalents, and marketable securities $185.5M at June 30, down from $219.6M at Dec 31.","Cash runway expected to fund operations into the first quarter of 2024.","R&D expenses $12.8M (+$0.9M YoY); G&A expenses $5.3M (-$0.7M YoY).","Upcoming milestones: NC318 Phase 2 update Q4 2022, NC410/NC762 data H2 2022, NC525 IND filing Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-086121","json":"https://secwatch.observer/filing/0001104659-22-086121.json","markdown":"https://secwatch.observer/filing/0001104659-22-086121.md","text":"https://secwatch.observer/filing/0001104659-22-086121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922086121/0001104659-22-086121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922086121/tm2222578d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:13:46.347085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}